.

13
- - 2011

site : www.eeasa.org

www.eeasa.org
,
,

:
MSD, Abbott, Roche, UCB, NOVARTIS,
Bristol - Myers Squibb, ACTELION, GENESIS, ALAPIS

 .. .....

'

,
,
,
.
, , ,
- .
,
,
, ,
.

137, ..: 111 46,
.: 210.25.85.536
-mail: elenivelli@gmail.com

internet :

www.eeasa.org

online

forum

.
/

: , ,

( HLA-DRB1),

, ,

()

C-

, -

. -

3:1

, -

4-6 .

, ,

- -

0,3 - 0,7% 10-20

, - - -

100.000 .

, -

(TNF). -

, .

, -

. -

. -

. -

10-15

50-60% .

, -

, -

"" .

etanercept

().

, -

4 .

-TNF

, :

" , ", -

10

, -

. ,

, -

,
.

TNF infliximab, etanercept, adalimumab
cetrolizumab golimumab.
-TNF .
(IL) 1 (kineret), IL-6 (tosilizumab)

(abatacept) -
(rituximab)
.


/
. . - / . . -

(Fibromyalgia, FM)

.
FM ,
'70 . 1990 FM (American College of Rheumatology, ACR).
.
, , ,
.
, , FM.
.
FM,
(.. , , , ,
).
FM.
FM .

FM
, , ,
, , .
,
.
, , , , , .

 1/3 FM

, -

, -

..

FM,

FM

,
FM -

FM -

( -

). FM

, -

FM.

. FM, ,
.

"" , FM, -

FM

. -

(75-80% ), -

30 ..

. , FM -

:
(70-90%) (~43 )
6-20% , 10% , 2%
: 3,4% - 0,5% (Wolfe 1996)
. :
1.

95%

2.

89%

3. -

86,4%

4.

87,8%

5.

32%

90% FM , 72% ,
67% , 33% , 80% ( San Antoine)
4 ..
90% FM ( 30%
)
26% 26%
30-50%, 60-70%

, 5945 $

10

 (, ,
). FM, "", .

,
:
)
(" "),

. ,
, , .
)
, ( ,
).
.

:
, ( -

),

"" . -

, ).

, ,

, -

stress .

- -

FM.

(90%)

/ .

, (30%)

(70% FM

, ,

, 65%

, ,

FM, 10%

. Raynaud -

).

FM
,
,

(, )
.

11



. . ,

.
, -

.
FM, (American College of Rheumatology, ACR)
1990 11 . ,
pinch-roll

(

) -

(), ,

"".

(1 ),

. -

, ,

. -

Heberden Bouchard) .

FM :
85-90% 55-100% , 40-50%
16%
: 1. 27% 2.
36-86% 3. 4. . Raynaud 5.

12

FM.

( )

FM. -

. FM -

, CRP), ,
.
FM.

FM.
, , Gougerot-Sjogren . () FM.


.
'
FM
,
, Gougerot-Sjogren

,
"" .
.
.
(Magnetic Resonance
Spectrometry) ,
, (ATP & )
.
.

. -

, ,

, -

, , FM.

FM -

(Rose-Waaler reaction).

MRS

ACR '

FM.

FM
:
stress
:

13


. :
FM,
25% .

- .

""
FM,
.
FM

.
FM

.
. :

FM 50-70% . FM
. ,

.
,
FM .


"" .
. :

FM,
.
""
.
, ,

,

. , ,
.


,

. FM

. (SPECT)
,

.
MRI.

FM
. ,
"". ,
, .

14

 .
,
. . NMDA , . ,


.

. :


. "" . , ,
.

.

16

.
:
FM. tilt test
.
. , ,
FM
.
.
:
( , ),
(Ebstein-Barr, Borrelia .).
.

FM .
,

.

FM,
.


FM
, . , ,

.
,
, .

.
,
,
.

,
.

.
.

. : ,

.
,
.
. :

FM.
.
,

.
stress, - ()
.
. :
FM,
.
,

(.. zolpidem, zopiclone), .
,
, .
. :

FM, .
. ,
.

. ,

.
,

. , , .

.
. :
()
FM. '

. ,

. , , .
. ,
.

FM IGF-1.

. ( ),
.

FM
, .
. ,
.

(
,
).
, "" . , stress,
.
Schultz
, "" .

17

.
, /

( ,
,
, , , ,
, .) , ,

. , ..

. ,
, .. , ,
,
, '
. ,
,

.

18

, , . ,

, , .



.
. ,

. , . ,
,
.
.



(. )
, , ,
.
. ,
,
.
,



.
. ,
, .
, ,
,
. ,
, .
,

.
.

,




/
,

19


. ' , .
,
. ,

, ,
,
.
.
, : 1. 2.
'
, 3. , .
,
,
.


.
.
( ,
),

, ,
(
). .
. ,

, ,


,






,

.



, , . ,

,
,

,



.

. ,
' ,


.

20

.






.



,




.
.


,

.
,


(

),

'
,


. ,
. , , ,

. ,


.
,





,
.
,

,
. ,

.



,
, .
. ,
,
, ,
,
,
,


.
. ,

,
,

. .

.

2010, 45
. , 45!
,
.
.
" ,
,
", .
.


(, 24
)

.
,
, (..
), ( ) .
" , -

22

, ", ,
. ",
,

".

,
- ,
, .
, , ;
, ,

, . "
, ,
,
, ",
.

 : ...
;
, -
- .
:

;
;
;
;
;

, :

;
""
;
;
,
, ,
.

24


&

..... : "
".
. . .
.
,

.
,

,
.
,
() 9/1.

;


.
,
6-12
.

25

 , , , ,



" "
-
.

;

6 - 12

, : (.. Endoxan, ),
, , ,
,
6 .

;
50%

15-20%
( 8%-15%)

( ),
- Ro (SSA) - La (SSB)

20%
( 24 > 300 mg
)
20%
(),
,

;
1 .

;
,
( 100 - 325 mg / )
(
)
(Immuran)
(Plaquenill)
, ,
.

""

;


"" (.. 7,5-10 mg presolon )

"stress" .

" ";

C3
DNA
26


" ";


:
,
, / / .

,

.

;
33%

- Ro (SSA)
10%
(3%
)
. !
(
).

;

.

;

;
50%
36
>30 .

;


.

;


.

: ,
, Plaquenil,
Endoxan, Immuran, Prezolon ,
Prezolon
. , ,
.

;




(, , ,
, ).

27

:
,
. C
, . ,
. , , .
: .
: 1 , 1 1 .
.
, ... .

:
, 2
.
, ,
,
.
.
: , .

.
, .
, ,
.
: 3
.
: , .

28

...

 Gusto ( )

,
,

"",
;

,
, ,
.

...

,
(300 .
25 . ).
,
: .
100 . ,
.
:
.

.
.
, , ,
,
.
,
.
:

.
:
, .

,
.
.
: 2-3
, .
: , .
, .

29

,
45 .
DNA
HPV ( ),

.
"" ,

, , ..,
. . , MD, PhD, PCOGRCR - .

,
.
, HPV

23

, -

, ,

- -

HPV,

HPV, . ,

- , DGGG.

HPV
23 , ,
.
30

 (
HPV
) HPV DNA ,
.
.
,
, .

: 8-9 . ,
, , ""
.
,
,

, - ' .
:
,
HPV.
:
: , , .
: HPV. 75% HPV.
, ,
.

12 - 15
16-26 . .

31

internet:

www.eeasa.org